ClinicalTrials.gg
CompletedNCT05657613Updated Oct 17, 2024

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

A Phase 1 interventional study of CYP450 Cocktail and Transporter Substrates with Pacritinib and Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib in Drug Interactions, sponsored by CTI BioPharma. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.

Read the detailed description

This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Part 1 will evaluate the effect of 14 days of pacritinib 200 mg BID at steady state on the systemic exposure of a cocktail of single doses of cytochrome P450 (caffeine, midazolam, omeprazole) and transporter substrates (digoxin, rosuvastatin, metformin) in 18 healthy male subjects who will participate in 2 treatment periods sequentially separated by a washout period. Part 2 will evaluate the effect of a CYP450 3A4 inducer (bosentan BID) for 7 days and the effect of a CYP450 3A4 inhibitor (fluconazole QD) for 7 days, on the PK of multiple doses of pacritinib 200 mg BID in 36 healthy male subjects. Safety and tolerability will be assessed by AEs, clinical laboratory tests, vital signs, ECGs, and physical examinations.

02

Conditions studied

  • Drug Interactions

Keywords

  • Pacritinib
  • Cytochrome P450 and Transporters
03

In context

Lead sponsor

CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is male 18 to 55 years of age, inclusive, at screening.
  • The subject has a of 18.0 to 32.0 kg/m2, inclusive, at screening.
  • The subject has a normal renal function ≥60 mL/min .
  • The subject is considered by the investigator to be in good general health as determined by medical history review, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening and check-in.
  • The male subjects will be sterile, or completely abstain from sexual intercourse, or agree to use, from check-in (Day -1) until 90 days following EOS/ET, one of the following approved methods of : male condom with spermicide or a sterile sexual partner; or use by female sexual partner of an IUD with spermicide, a female condom with spermicide, a contraceptive sponge with spermicide, an intravaginal system, a diaphragm with spermicide, a cervical cap with spermicide, or oral, implantable, transdermal, or injectable contraceptives. The subject will refrain from sperm donation from check-in (Day -1) until 90 days following study completion (Day 31 for Part 1 and Day 24 for Part 2).
  • The subject must have adequate venous access for blood draws.
  • The subject agrees to comply with all protocol requirements.
  • The subject is able to provide written .

Additional Inclusion Criteria for Part 1:

  • The subject has a documented result of genotype testing for CYP2C19 *1/*1 suggesting normal metabolizers.

Exclusion criteria

Exclusion Criteria:

  • The subject has a history of any conditions including the following:
  • Asthma treated with oral systemic within the past 6 months
  • Diabetes mellitus (types 1 or 2), with the exception of gestational diabetes
  • Thyroidectomy or thyroid disease that required medication within the past 12 months
  • Serious angioedema episodes within the previous 3 years or requiring medication in the previous 2 years
  • Head trauma resulting in a diagnosis of traumatic brain injury other than concussion
  • Known clinically relevant history or presence of significant respiratory (eg, interstitial lung disease), GI (eg, GI ulceration, peptic ulceration, GI bleeding, gastroesophageal reflux, or other GI disease affecting gastroesophageal junction), renal, hepatic (eg, known hepatic or biliary abnormalities), hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic (eg, diabetes) and dermatological or connective tissue disease.
  • The subject has a value >1.5 × for any of the following: , partial thromboplastin time, and international normalized ratio.
  • The subject has a seated systolic blood pressure >160 mm Hg or ≤90 mm Hg and a diastolic blood pressure of >100 mm Hg or ≤50 mm Hg, inclusive, at screening and check-in unless deemed not clinically significant by the investigator, as approved by the sponsor.
  • The subject has a seated pulse rate of \<50 bpm or >100 bpm and/or an oral body temperature \<35.0°C or >37.5°C when vital signs are measured at screening and check-in.
  • The subject has a clinically significant illness, including viral syndromes, within 3 weeks of dosing.
  • The subject has a known clinically significant chronic viral infection (eg, human T-cell lymphotropic virus I or II).
  • The subject has a history or clinical manifestation of clinically significant cardiovascular, pulmonary, hepatic (eg, hepatitis), renal, hematologic, gastrointestinal (eg, celiac disease, peptic ulcer, gastroesophageal reflux, inflammatory bowel disease), metabolic, allergic, dermatological, neurological, or psychiatric disorder (as determined by the investigator; appendectomy and cholecystectomy [within 3 to 6 months] are not considered to be clinically significant procedures).
  • The subject has a history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or risk factors for torsades de pointes (eg, heart f failure, hypokalemia).
  • The subject has evidence or a history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of the first dose of study drug), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. Exceptions to this criterion (eg, stable, mild joint disease unassociated with collagen vascular disease) may be made following discussions with the medical monitor.
  • The subject has evidence of neutropenia or any other blood dyscrasia determined to be clinically significant by the investigator.
  • The subject has history of a gastrointestinal bleeding.
  • The subject has a history of a bleeding disorder diagnosed by a doctor (eg, coagulation factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with blood draws.
  • The subject has receipt of blood products within 2 months prior to check-in (Day -1).
  • The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  • The subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  • The subject has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening, check-in, or throughout the study.
  • The subject has a history or presence of an abnormal , which, in the investigator's opinion, is clinically significant; >450 msec, or factors that increase the risk for QTc interval prolongation (eg, heart failure, hypokalemia [defined as serum potassium \<3.0 mEq/L that is persistent and to correction], or a history of long QT interval syndrome).
  • The subject has a history of relevant drug and/or food allergies (ie, allergy to digoxin, caffeine, midazolam, omeprazole, rosuvastatin, metformin, bosentan, and fluconazole or ) or a previous allergic reaction to phenytoin or carbamazepine (applicable for Group B subjects).
  • The subject has a history of lymphoma, leukemia or other types of .
  • The subject has a current or recent (\<30 days before screening) history of clinically significant bacterial, fungal, or mycobacterial infection.
  • The subject has a current or recent (\<30 days before screening) history of vitamin B12 deficiency.
  • The subject is unable to tolerate oral medication.
  • The subject has any major surgery within 4 weeks of study drug administration.
  • The subject has a family history of sudden cardiac death not clearly due to acute myocardial infarction.
  • The subject has any screening or baseline laboratories outside the normal range and deemed clinically significant.
  • The subject has used any prescription or over-the-counter medications, including herbal or nutritional supplements, within 14 days of check-in.
  • The subject has any condition possibly affecting drug absorption (eg, previous surgery on the gastrointestinal tract, including removal of parts of the stomach, bowel, liver, gallbladder, or pancreas, with the exception of appendectomy).
  • The subject has used any of the prohibited medications (targeted CYP inducers or inhibitors) from within 15 days (or 5 half-lives, whichever is longer) before the first dose of study drug.
  • The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange- containing products (eg, marmalade), or caffeine- or xanthine-containing products or other inhibitors, inducers, or transporter substrates within 48 hours before the first dose of study drug and throughout the study.
  • The subject has consumed pomegranate or pomegranate juice, pomelo fruits or pomelo juice, or alcohol within 72 hours before check-in on Day -1.
  • The subject has a positive test result for surface antigen, virus antibody, or types 1 or 2 antibodies at screening.
  • The subject is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and throughout the study.
  • The subject has received treatment in another clinical study of an drug (or medical device) or investigational vaccine within 30 days or 5 half-lives (whichever is longer) prior to check-in.
  • The subject has previously received pacritinib.
  • The subject is not suitable for entry into the study in the opinion of the investigator.
  • Use of any other prescription medications and/or products within 14 days prior to check-in (Day -1) and during the entire study, unless deemed acceptable by the investigator in consultation with the sponsor. In addition, use of any over-the-counter, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) from 7 days prior to check-in (Day -1) and during the entire study, unless deemed acceptable by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    CYP450 Cocktail and Transporter Substrates with Pacritinib

    This is the first part of the study which is an open-label, single-center, 1-way DDI study designed to assess the effect of pacritinib 200 mg BID at steady state on the systemic exposure of a cocktail of cytochrome P450 (caffeine, midazolam, and omeprazole) and transporter substrates (digoxin, rosuvastatin, and metformin) in 18 healthy male subjects.

    Drug: CYP450 Cocktail and Transporter Substrates with Pacritinib

  • Experimental
    CYP450 3A4 inducer (Bosentan) with Pacritinib

    The second part of the study comprises of 2 arms. This is the first arm Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of bosentan 125 mg BID (approximately 12 hours apart) All the doses will be administered with approximately 240 mL of water.

    Drug: Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib

  • Experimental
    CYP450 3A4 inhibitor (Fluconazole) with Pacritinib

    This is the second arm of Part 2 of the study: Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of fluconazole 200 mg QD

    Drug: Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib

Interventions

  • DrugCYP450 Cocktail and Transporter Substrates with Pacritinib

    Drug page: Pacritinib

    Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter) Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg) Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg. Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg.

    Also known as: Vonjo

  • DrugPart 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib

    Drug page: Pacritinib

    Days 1-7: Oral doses of pacritinib 200 mg BID Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID

    Also known as: Vonjo

  • DrugPart 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib

    Drug page: Pacritinib

    Days 1-7: Oral doses of pacritinib 200 mg BID Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD.

    Also known as: Vonjo

06

What researchers measure

Primary outcomes

  1. Change in area under curve (AUC) of individual substrates between cocktail alone and cocktail combined with pacritinib administration

    Change in the systemic exposure of digoxin, midazolam omeprazole, rosuvastatin, caffeine and metformin when co-adminstered with pacritinib

    Time frame: Through study completion, a maximum of 14 days for pacritinib

  2. Change in maximum plasma concentration (Cmax) of individual substrates between cocktail alone and cocktail combined with pacritinib administration

    To assess the effect of pacritinib on the systemic exposure of digoxin, midazolam, omeprazole, rosuvastatin, caffeine, and metformin

    Time frame: Through study completion, a maximum of 14 days for pacritinib

  3. Change in area under curve (AUC) of pacritinib alone and pacritinib + bosentan administration

    To assess the effect of bosentan (CYP450 3A4 inducer) on the systemic exposure of multiple doses of pacritinib

    Time frame: Through completion, a maximum of 14 days for pacritinib

  4. Change in Cmax of pacritinib alone and pacritinib + bosentan administration

    To assess the effect of bosentan (CYP450 3A4 inducer) on the peak exposure of multiple doses of pacritinib

    Time frame: Through study completion, a maximum of 14 days for pacritinib

  5. Change in AUC of pacritinib alone and pacritinib + fluconazole administration

    To assess the effect of fluconazole (CYP450 3A4 inhibitor) on the systemic exposure of multiple doses of pacritinib

    Time frame: Through study completion, a maximum of 14 days for pacritinib

  6. Change in Cmax of pacritinib alone and pacritinib + fluconazole administration

    To assess the effect of fluconazole (CYP450 3A4 inhibitor) on the systemic peak exposure of multiple doses of pacritinib

    Time frame: Through study completion, a maximum of 14 days for pacritinib

Secondary outcomes

  1. Number and severity of adverse events with cocktail substrates in the presence of pacritinib

    Any adverse event will be monitored and recorded (including an abnormal clinical laboratory results, an abnormal electrocardiogram), symptom or diseases temporarily associated with the use of a study drug, whether considered related to study drug or not. To assess safety and tolerability of multiple doses of pacritinib coadministered with digoxin, caffeine, midazolam, omeprazole, rosuvastatin, and metformin in healthy male subjects.

    Time frame: Up to 31 days

  2. Number and severity of adverse events with pacritinib in the presence of CYP450 3A4 inducer

    Any adverse event will be monitored and recorded (including an abnormal clinical laboratory results, an abnormal electrocardiogram), symptom or diseases temporarily associated with the use of a study drug, whether considered related to study drug or not. To assess safety and tolerability of multiple doses of pacritinib coadministered with bosentan in healthy male subjects.

    Time frame: Up to 31 days

  3. Number and severity of adverse events with pacritinib in the presence of CYP450 3A4 inhibitor

    Any adverse event will be monitored and recorded (including an abnormal clinical laboratory result, an abnormal electrocardiogram), symptom or diseases temporarily associated with the use of a study drug, whether considered related to study drug or not. To assess safety and tolerability of multiple doses of pacritinib coadministered with fluconazole in healthy male subjects.

    Time frame: Up to 31days

07

Study locations

1 site
  • Site 1
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jun 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 20, 2022
StartActual
Jan 3, 2023
Primary completionActual
Jun 8, 2023
CompletionActual
Jun 8, 2023
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05657613
Lead sponsor
CTI BioPharma
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Jan 3, 2023
Primary completion
Jun 8, 2023
Completion
Jun 8, 2023
Last update
Oct 17, 2024

Study contacts

Buckley
study director · CTI BioPharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion